In 2025, there were a total of 945 integrated projects, with 74 being in Phase III clinical development and 25 focused on commercial manufacturing. A record-breaking 209 new integrated projects were initiated in the same year, with around half of them stemming from clients based in the United States. Complex modalities form the primary growth driver for WuXi Biologics.